Skip to main content

Advertisement

Table 2 Factors associated with pre-treatment loss to follow-up among bacteriologically confirmed TB patients diagnosed in 21 township health centres of the Mandalay Region of Myanmar between January and June 2017

From: Pre-treatment loss to follow-up and treatment delay among bacteriologically-confirmed tuberculosis patients diagnosed in Mandalay Region, Myanmar

Characteristics Total (n) PTLFU (n (%)) RR (95%CI) aRR (95%CI)
Total 1365 114 (8.4)   
Age (years)
 < 15 8 2 (25.0) 3.0 (0.9–10.2) 1.3 (0.3–5.4)
 15–44 805 67 (8.3) Ref Ref
 45–64 425 38 (8.9) 1.1 (0.7–1.6) 0.9 (0.6–1.4)
 ≥ 65 127 7 (5.5) 0.7 (0.3–1.4) 0.6 (0.2–1.3)
Gender
 Male 1018 86 (8.5) Ref Ref
 Female 347 28 (8.1) 0.9 (0.6–1.4) 1.0 (0.65–1.55)
Phone number
 Recorded 38 1 (2.6) 0.3 (0.0–2.2)  
 Not recorded 1327 113 (8.5) Ref  
HIV status
 Positive 71 13 (18.3) 3.5 (2.0–6.1) 2.7 (1.4–5.0)
 Negative 1060 55 (5.2) Ref Ref
 Unknown 234 46 (19.7) 3.8 (2.6–5.5) 4.2 (2.7–6.4)
History of TB treatment
 Yes 110 22 (20.0) 2.5 (1.6–3.9) 1.7 (0.9–2.8)
 No 864 68 (7.9) Ref Ref
 Unknown 391 24 (6.1) 0.8 (0.5-1.2) 0.5 (0.3–0.8)
Sputum result
 Smear positive 1303 95 (7.3) Ref Ref
 Smear negative Xpert positive 62 19 (30.7) 4.2 (2.8–6.4) 2.6 (1.4–4.6)
Site of sputum microscopy
 Low volume 308 11 (3.6) Ref Ref
 Moderate volume 328 27 (8.2) 2.3 (1.2–4.6) 2.2 (1.1–4.4)
 High volume 729 76 (10.4) 2.9 (1.6–5.4) 1.7 (0.9–3.2)
  1. PTLFU pre-treatment loss to follow-up, TB tuberculosis, RR relative risk, aRR adjusted relative risk (adjusted for age, gender, HIV status, history of TB treatment, sputum result, site of sputum microscopy), Ref reference group. Text in boldface indicates the statistical significance at p value < 0.001